Blue Owl Cuts Loparex Loan Marks to Pennies
Blue Owl's retail private credit fund significantly reduced the value of its Loparex loans, with second-lien marks dropping to around 5 cents. OBDC, a publicly traded BDC, placed Loparex on non-accrual, and Moody's warned of a potential Chapter 11 filing. Loparex missed a June interest payment and is operating under a forbearance agreement. The company's sponsor, Pamplona Capital Management, did not comment.
How this was made
The 30-second read
Why it matters
The write‑downs could lead to an impairment charge for OBDC and affect its NAV, influencing investor sentiment toward BDCs.
Market read
New credit deterioration news for OBDC may drive short‑term price action and prompt re‑evaluation of BDC credit risk.
What to watch
Potential upside if Loparex restructures or secures new equity, which could mitigate losses for OBDC.
Background
Blue Owl's retail private credit fund suffered steep markdowns on Loparex loans after a failed M&A recapitalization, prompting OBDC to place the loans on non‑accrual.
Ticker impact
OBDC placed Loparex loans on non‑accrual and reported severe markdowns to 5‑22 cents, indicating credit deterioration.
downside pressure on OBDC equity
New loan write‑downs and rating agency default comments suggest higher credit risk and possible future losses.
Market effects
Highlights stress in private credit and BDC sector, may trigger broader scrutiny of loan valuation practices.
US BDC market could see heightened volatility as investors reassess credit exposure.
Limited to US-listed BDCs; no direct global impact.
Counterpoint
If OBDC's overall non‑accrual rate remains low, the Loparex issue may be isolated and not materially affect the broader portfolio.
Key entities
- CompanyLoparex
Specialty paper and liner manufacturer whose loans were heavily marked down.
- Public CompanyOBDC
Publicly traded business development company that holds Loparex loans.
